Pyridostigmine compared with placebo for postural tachycardia syndrome
Tests pyridostigmine against a placebo in people with postural tachycardia syndrome.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- A Study of Pyridostigmine in Postural Tachycardia Syndrome
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- Oct 2006
- Expected to end
- Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- pyridostigmine
- Placebo
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with postural tachycardia syndrome (POTS). It compares pyridostigmine with a placebo (dummy pill) over 3 days.
- Age
- 15 Years to 55 Years
- Sex
- All sexes can join
- Disease stage
- POTS diagnosis: heart rate rises by 30 bpm or more within 5 minutes of a head-up tilt test, plus symptoms when standing, such as weakness, lightheadedness, blurred vision, nausea, palpitations or trouble thinking. Both must be present.
- Earlier treatment
- People who were treated with pyridostigmine for POTS before cannot join. No pyridostigmine in the past month.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Failure of other organs, or a body-wide illness that could affect the nervous control of the body or the ability to take part
- Underactive or overactive thyroid
- Clinically significant heart artery disease
- Medicines that could interfere with the nervous system tests
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Diagnosis of postural tachycardia syndrome using the following criteria:
- Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt
- Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking; Both criteria must be fulfilled
Who cannot take part
- Medications that could interfere with autonomic testing
- Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month
- Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
- Clinically significant coronary artery disease
- Pregnant or lactating women
- Hypothyroidism or hyperthyroidism
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 55 years old?
Where in United States
- Mayo ClinicRochester, United StatesContact: Toni GehrkingTaking people
About the trial
What the trial wants to find out
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
The 2 groups in the trial
- pyridostigmineExisting treatment, for comparison
Active study drug
- PlaceboPlacebo, for comparison
Control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
- Plain-language title
- Pyridostigmine compared with placebo for postural tachycardia syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT00409435, who can take part
- Record updated
- 5 March 2026